Phaseline

Companies › Salspera

Salspera: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Salmonella-IL2 (Saltikva)
Attenuated Salmonella Typhimurium expressing IL-2
IL2Phase 2Metastatic Pancreatic CancerDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04589234Salmonella-IL2 (Saltikva)Phase 2Metastatic Pancreatic CancerOncologyDec 2030

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics Synthekine Nektar Therapeutics HCW Biologics Asher Biotherapeutics Regeneron Pharmaceuticals Iovance Biotherapeutics

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.